NIH invests $3.19M in innovative microneedle drug delivery system development by Triton Systems

Contract Overview

Contract Amount: $3,191,607 ($3.2M)

Contractor: Triton Systems, Inc.

Awarding Agency: Department of Health and Human Services

Start Date: 2023-09-30

End Date: 2026-01-14

Contract Duration: 837 days

Daily Burn Rate: $3.8K/day

Competition Type: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Number of Offers Received: 3

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG

Place of Performance

Location: CHELMSFORD, MIDDLESEX County, MASSACHUSETTS, 01824

State: Massachusetts Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $3.2 million to TRITON SYSTEMS, INC. for work described as: DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG Key points: 1. Contract focuses on developing a low-cost, remotely controllable, disposable microneedle transdermal drug delivery device. 2. The technology aims to deliver FDA-approved transdermal drugs, potentially expanding treatment options. 3. Research and Development in Physical, Engineering, and Life Sciences is a key area for NIH investment. 4. The contract is a Definitive Contract with a Firm Fixed Price, indicating clear cost expectations. 5. The duration of the contract is 837 days, suggesting a substantial development timeline. 6. The contract was awarded under Full and Open Competition after Exclusion of Sources, implying a competitive process with specific justifications.

Value Assessment

Rating: good

The contract value of $3.19 million for the development of a novel drug delivery system appears reasonable given the R&D nature of the work. Benchmarking against similar early-stage technology development contracts is challenging due to the unique nature of the 'SatiORx' device. However, the firm fixed-price structure suggests that the contractor has assessed the risks and costs associated with development, providing a degree of cost certainty for the government.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under 'Full and Open Competition after Exclusion of Sources.' This indicates that while the competition was open, there were specific reasons for excluding certain potential sources, possibly related to intellectual property, prior development, or unique capabilities. The number of bidders is not explicitly stated, but the designation suggests a competitive process was initiated and evaluated.

Taxpayer Impact: The competitive nature, even with exclusions, aims to ensure the government receives the best value and innovative solutions at a fair price, preventing sole-source price inflation.

Public Impact

Patients who could benefit from more accessible and potentially less invasive drug delivery methods. The development of a versatile transdermal drug delivery platform applicable to various FDA-approved drugs. Advancement of medical technology within the United States, fostering innovation in the healthcare sector. Potential for job creation in research, development, and future manufacturing related to the technology.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

The novelty of the technology may present unforeseen development challenges and risks.
Reliance on specific expertise for the development of the microneedle and remote control systems.
The success of the device is contingent on future FDA approvals for specific drug applications.

Positive Signals

Focus on a low-cost, disposable design could lead to widespread adoption and affordability.
The remote control feature offers potential for enhanced patient compliance and remote healthcare delivery.
Development of a platform technology applicable to a wide range of transdermal drugs.

Sector Analysis

This contract falls within the Research and Development (R&D) sector, specifically focusing on medical devices and drug delivery systems. The market for transdermal drug delivery is growing, driven by the demand for non-invasive and convenient administration methods. Comparable spending in this area often involves significant investment in early-stage innovation, with contracts ranging from small grants for proof-of-concept to larger awards for prototype development and clinical trials.

Small Business Impact

The contract does not indicate any specific small business set-aside or subcontracting requirements. The primary contractor, Triton Systems, Inc., is not identified as a small business in the provided data. Therefore, the direct impact on the small business ecosystem is likely minimal unless the prime contractor engages small businesses for subcontracting opportunities.

Oversight & Accountability

The contract is managed by the National Institutes of Health (NIH), a component of the Department of Health and Human Services (HHS). Oversight would typically involve program managers monitoring progress against milestones, adherence to budget, and technical performance. Transparency is generally maintained through contract databases and public reporting, though specific developmental details may be proprietary. The HHS Office of Inspector General would have jurisdiction over potential fraud, waste, or abuse.

Related Government Programs

National Institutes of Health Research Grants
Medical Device Development Programs
Transdermal Drug Delivery Research
Biotechnology and Pharmaceutical R&D

Risk Flags

Technology Development Risk
Regulatory Approval Uncertainty
Market Adoption Challenges
Manufacturing Scalability Concerns

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $3.2 million to TRITON SYSTEMS, INC.. DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG

Who is the contractor on this award?

The obligated recipient is TRITON SYSTEMS, INC..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $3.2 million.

What is the period of performance?

Start: 2023-09-30. End: 2026-01-14.

What is the specific innovation behind the 'SatiORx' device compared to existing transdermal delivery methods?

The 'SatiORx' device aims to differentiate itself through a combination of features: it is designed to be a very low-cost, remotely controllable, and disposable microneedle patch. Unlike many existing transdermal patches that rely on passive diffusion, microneedles create micro-channels in the skin to enhance drug permeation, potentially allowing for faster onset and higher bioavailability. The 'remotely controllable' aspect suggests an active delivery mechanism, possibly triggered wirelessly, which could offer precise dosing and improved patient adherence. The 'disposable' nature and 'low-cost' design are intended to make it a more accessible and practical option for a wider range of therapeutic applications compared to more complex or reusable systems.

How does the $3.19 million investment compare to typical R&D funding for similar novel medical device technologies?

The $3.19 million investment for the development of the 'SatiORx' microneedle device appears to be within a reasonable range for early-stage R&D in novel medical technologies, particularly for a Definitive Contract awarded under full and open competition. Funding for such projects can vary significantly based on the technology's maturity, the complexity of development, and the specific goals (e.g., proof-of-concept, prototype development, preclinical testing). NIH grants and contracts in this area often range from hundreds of thousands to several million dollars. This particular award suggests a significant commitment to advancing the technology from concept towards a functional prototype, covering aspects like material science, engineering, and initial feasibility testing.

What are the primary risks associated with the development and eventual market adoption of this microneedle technology?

The primary risks associated with the 'SatiORx' development include technical challenges in manufacturing the microneedles consistently at a low cost and ensuring their reliability and safety for transdermal delivery. Ensuring the remote control mechanism is robust, secure, and user-friendly presents another hurdle. From a market adoption perspective, regulatory approval (FDA) for specific drug applications will be critical and can be a lengthy and expensive process. Furthermore, patient and physician acceptance of microneedle technology, despite its potential benefits, needs to be cultivated. Finally, the economic viability hinges on achieving the promised low-cost manufacturing at scale, which is often a significant challenge for novel medical devices.

What is Triton Systems, Inc.'s track record in developing similar advanced medical or drug delivery technologies?

Triton Systems, Inc. has a history of developing advanced materials and technologies, often for defense and aerospace applications, but also extending into medical and other commercial sectors. While specific details on their prior work in microneedle or transdermal drug delivery systems are not provided in this data snippet, their general expertise in materials science, microfabrication, and complex system integration suggests a capability to undertake such a project. Their portfolio often includes innovative solutions requiring precision engineering and specialized material properties, which are relevant to the development of a sophisticated device like 'SatiORx'. Further investigation into their specific project history would be needed for a comprehensive assessment.

How might the 'remotely controllable' feature of this device impact future healthcare delivery models?

The 'remotely controllable' aspect of the 'SatiORx' device has the potential to significantly impact future healthcare delivery models by enabling more precise and convenient drug administration. It could facilitate telehealth by allowing healthcare providers to initiate or adjust medication delivery remotely, improving patient adherence and reducing the need for in-person visits, especially for chronic conditions requiring regular dosing. This feature could also be crucial for medications requiring specific timing or controlled release profiles that are difficult to achieve with passive patches. Furthermore, it opens possibilities for emergency response or specialized therapeutic applications where immediate, controlled drug delivery is necessary. The disposable nature combined with remote control could streamline home healthcare and reduce the burden on caregivers.

What are the potential long-term implications for the pharmaceutical industry if this technology proves successful?

If the 'SatiORx' technology proves successful, it could have substantial long-term implications for the pharmaceutical industry. It offers a new platform for drug delivery that could potentially enhance the efficacy and patient compliance for a wide range of existing and new drugs, possibly extending patent life or creating new market opportunities. Companies might reformulate drugs for transdermal delivery via microneedles, seeking advantages over oral or injectable routes. The low-cost, disposable nature could make treatments more accessible, particularly in resource-limited settings. This could shift focus from traditional pill or injection manufacturing towards advanced patch technologies, potentially requiring significant investment in R&D and manufacturing capabilities within the pharmaceutical sector.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: 75N91023R00041

Offers Received: 3

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 330 BILLERICA RD, CHELMSFORD, MA, 01824

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $3,191,607

Exercised Options: $3,191,607

Current Obligation: $3,191,607

Actual Outlays: $3,191,607

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline